18 August 2017 - Hours after Pfizer announced the news of regulatory approval for its drug Besponsa (inotuzumab ozogamicin) in the USA, the company suffered a setback with its attempts to sell the drug in the UK.

Cost-effectiveness watchdog the NICE has not recommended that funding be provided by the National Health Service for the treatment for relapsed or refractory CD22 positive B-cell precursor acute lymphoblastic leukaemia.

In recent months, Pfizer has made a major effort to show the UK public and policy makers the reason why innovation is so costly for drug developers and how it tries to price its medicines fairly, The Pharma Letter has witnessed, so it is perhaps not surprising that the company has reacted angrily to the NICE’s final appraisal determination.

Read The Pharma Letter article